PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages
Michael Pitter, Ilona Kryczek, Hongjuan Zhang, Nisha Nagarsheth, Houjun Xia, Zhenyu Wu, Yuzi Tian, Karolina Okła, Peng Liao, Weichao Wang, Jiajia Zhou, Gaopeng Li, Heng Lin, Linda Vatan, Sara Grove, Shuang Wei, Yongqing Li, Weiping Zou
Abstract
Tumor-associated macrophages (TAMs) shape tumor immunity and therapeutic efficacy. However, it is poorly understood whether and how post-translational modifications (PTMs) intrinsically affect the phenotype and function of TAMs. Here, we reveal that peptidylarginine deiminase 4 (PAD4) exhibits the highest expression among common PTM enzymes in TAMs and negatively correlates with the clinical response to immune checkpoint blockade. Genetic and pharmacological inhibition of PAD4 in macrophages prevents tumor progression in tumor-bearing mouse models, accompanied by an increase in macrophage major histocompatibility complex (MHC) class II expression and T cell effector function. Mechanistically, PAD4 citrullinates STAT1 at arginine 121, thereby promoting the interaction between STAT1 and protein inhibitor of activated STAT1 (PIAS1), and the loss of PAD4 abolishes this interaction, ablating the inhibitory role of PIAS1 in the expression of MHC class II machinery in macrophages and enhancing T cell activation. Thus, the PAD4-STAT1-PIAS1 axis is an immune restriction mechanism in macrophages and may serve as a cancer immunotherapy target.